Figure 1
PRISMA flow diagram of study screening and selection.
Figure 2
Mean Difference of Time with Glucose in Range (%) for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100.
Figure 3
Mean Difference of HBa1C (%) Change from Baseline for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100.
Figure 4
Odds Ratio of Hypoglycemia for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100.
Figure 5
Odds Ratio of Any Adverse Outcome for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100.
Figure 6
Mean Difference of Fasting Plasma Glucose (mg/dL) for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100.
Figure 7
Mean Difference of Body Weight (kg) Change from Baseline for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100.
Figure 8
Mean Difference of Insulin Dose Difference (UI) for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100.
Figure 9
Forrest Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Serious Adverse Event.
Figure 10
Forrest Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Any Adverse Event Probably related to Basal Insulin*.
Figure 11
Forrest Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Injection Site Reaction.
Figure 12
Forrest Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Hypersensitivity Event.
Figure 13
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Any Adverse Outcome.
Figure 14
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Serious Adverse Event.
Figure 15
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Any Adverse Event Probably related to Basal Insulin.
Figure 16
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Injection Site Reaction.
Figure 17
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Hypersensitivity Reaction.
Figure 18
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Hypoglycemia Alert.
Figure 19
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Clinically Significant or Severe Hypoglycemia.
Figure 20
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for HBa1C (%) Change from Baseline.
Figure 21
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Fasting Plasma Glucose (mg/dL) Change from Baseline.
Figure 22
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Body Weight (kg) Change from Baseline.
Figure 23
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Time with Glucose in Range (%).
Figure 24
Funnel Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 for Insulin Dose Difference (UI).
Figure 25
Mean Difference of Time with Glucose in Range (%) for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 26
Mean Difference of HBa1C (%) Change from Baseline for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 27
Mean Difference of Fasting Plasma Glucose (mg/dL) Change from Baseline for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 28
Mean Difference of Body Weight (kg) Change from Baseline for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 29
Mean Difference of Insulin Dose Difference (UI) for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 30
Odds Ratio of Any Adverse Outcome for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 31
Odds Ratio of Serious Adverse Event for Forrest Plot of Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 32
Odds Ratio of Any Adverse Event Probably related to Basal Insulin for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.)*.
Figure 33
Odds Ratio of Injection Site Reaction for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 34
Odds Ratio of Hypersensitivity Reaction for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 35
Odds Ratio of Hypoglycemia Alert for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).
Figure 36
Odds Ratio of Clinically Significant or Severe Hypoglycemia for Once-Weekly Icodec vs. Once-Daily Insulin Glargine U100 without Bajaj study (66 Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. 2021;44(7):1586-94.).